Article3 Biotech2018
Antimycobacterial potentials of quercetin and rutin against
Article in 3 Biotech, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- The Pharmacological Spectrum of Hispidulin: A Thorough Systematic Review and Meta-analysis.Cell biochemistry and biophysics · 2025Pooled it
- Cefpiramide RestrictsACS medicinal chemistry letters · 2026Article
- Integrative computational approaches, molecular docking, and dynamic simulations reveal the antimycobacterial activity of fisetin as a potential inhibitor of Mycobacterium tuberculosis.Journal of computer-aided molecular design · 2026Article
- Bioactive Compounds Discovery from French Guiana Plant Extracts Through Antitubercular Screening and Molecular Networking.Plants (Basel, Switzerland) · 2025Article
- Selected Medicinal Plants Used in the Treatment and Management of Tuberculosis and Related Symptoms in South Africa.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Design and synthesis of natural antibacterial derivatives for ocular tuberculosis: a comprehensive review.Frontiers in pharmacology · 2025Review
- The advances in adjuvant therapy for tuberculosis with immunoregulatory compounds.Frontiers in microbiology · 2024Review
- Quercetin: A Potential Polydynamic Drug.Molecules (Basel, Switzerland) · 2023Review
- Advanced drug delivery and therapeutic strategies for tuberculosis treatment.Journal of nanobiotechnology · 2023Review
- Article
- Promising Antimycobacterial Activities of Flavonoids againstMolecules (Basel, Switzerland) · 2022Review
- Metabolomics analyses of traditional Chinese medicine formula Shuang Huang Lian by UHPLC-QTOF-MS/MS.Chinese medicine · 2022Article
- Plants derived therapeutic strategies targeting chronic respiratory diseases: Chemical and immunological perspective.Chemico-biological interactions · 2020Review
- Potential Anti-Tuberculosis Activity of the Extracts and Their Active Components ofAntibiotics (Basel, Switzerland) · 2020Article
- Flavonoid Mixture InhibitsMolecules (Basel, Switzerland) · 2019Article
- Article
- Physical characteristics of quercetin pulmospheres using combination of alginate-carrageenan: Effect of polymer concentration.Journal of advanced pharmaceutical technology & researchArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Quercetin and rutin, two flavonoids were examined for antimycobacterial activities against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.